SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MDCO: Medicines Company -- Ignore unavailable to you. Want to Upgrade?

To: David Howe who wrote (98)9/7/2003 9:06:38 PM
From: Mike  Respond to of 125
 
Research a little further and you will understand. MLNM is a dirtbag company and has dirtbag reps. Integrilin sales are going to the skids and it is MLNM's only product. So you tell me why it wouldn't effect MLNM with Angiomax taking market share from MLNM?

Sorry for the strong words but I have been bashed by MLNM lovers that don't care to see the truth. MLNM has a lot of promise and no delivery. The executives of MLNM are out for themselves and could care less about who ends up with the bag.

Mike



To: David Howe who wrote (98)9/9/2003 12:19:56 PM
From: Mike  Read Replies (1) | Respond to of 125
 
New 52 week high for MDCO. I love the controversy caused by MDCO. I love taking on companies like MLNM and putting them to shame.

Angiomax is a better drug and a better tool for everyone involved in the care of a PCI patient. The only ones who loss are the MLNM investors and the shorts of MDCO.

Have a nice day,
Mike


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News